Mereo BioPharma Group plc (MPH.L) (MPH) Share Price, News & Analysis

Company Overview

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 49,264 shs
• Average Volume: 333,975 shs
• Market Capitalization: £89.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MPH Stock Analysis - Frequently Asked Questions

How were Mereo BioPharma Group plc (MPH.L)'s earnings last quarter?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) announced its quarterly earnings data on Tuesday, September, 29th. The company reported ($105.00) earnings per share (EPS) for the quarter.

How do I buy shares of Mereo BioPharma Group plc (MPH.L)?

Shares of MPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Mereo BioPharma Group plc (MPH.L) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mereo BioPharma Group plc (MPH.L) investors own include Bausch Health Cos (BHC), Enanta Pharmaceuticals (ENTA), Advanced Micro Devices (AMD), American Tower (AMT), Bristol Myers Squibb (BMY), Galaxy Digital (BRPHF) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 9/29/2020
• Today: 8/23/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:MPH
• CIK: N/A
• Web: mereobiopharma.com
• Phone: 44 33 3023 7300
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 164.26
• Current Ratio: 2.98
• Quick Ratio: 2.92

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: 1.55
• Book Value: GBX 7.20 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 338,713,984
• Free Float: N/A
• Market Cap: £89.76 million
• Optionable: Not Optionable
• Beta: N/A